OR WAIT null SECS
The American College of Rheumatology (ACR) has published guidance regarding the management of juvenile idiopathic arthritis, with emphasis placed on the treatment of systemic JIA and oligoarthritis, as well as non-pharmacologic therapies.
The American College of Rheumatology (ACR) has published guidance regarding the treatment and management of juvenile idiopathic arthritis (JIA), with emphasis placed on the treatment of oligoarthritis, systemic JIA (both with and without macrophage activation syndrome (MAS), monitoring drug toxicities, immunizations, and radiographic imaging. The original guidelines were published in 2011 and 2013.
“As rheumatologists, our patients and caregivers expect us to review the literature and weigh the evidence so that we can suggest the best treatments, while also considering their preferences,” stated Karen Onel, MD, lead investigator of the guidelines. “The field has changed tremendously since the 2011 and 2013 efforts, so we needed to adapt our guidance to the times in order to offer our patients the most nimble and state-of-the-art care possible.”